犬内脏利什曼病(CVL)是犬中表现出的最具侵袭性和致死性的利什曼病形式,是主要的公共卫生问题。尽管有足够灵敏的分子工具用于CVL诊断,它们在疾病传播的主要点是无法获得的,在这种情况下,血清诊断已被用作流行病学控制的替代工具。作为开发更准确的免疫诊断方法的尝试,多年来已经测试了许多抗原,在不同的平台上。这篇综述旨在访问报告可用于CVL血清诊断的新抗原的研究。从2016年1月到2021年3月发表的文章从GoogleScholar检索,科学直接,和PubMed,使用“犬内脏利什曼病”和“血清诊断”作为关键词。总的来说,确定了1527篇文章,其中42项是根据排除因素选择的。灵敏度,特异性,样本量,和样本质量数据通过手工整理提取和分析。在选定的文章中,26预期的ELISA,这使得对这些研究进行了更彻底的比较和批判性审查。可溶性利什曼原虫抗原(SLA)和A2蛋白在53.8和46.15%的这些文章中用作对照,分别,并进行了单独评估;它们的频繁使用受到质疑。随后,评估其他分析平台的文章,如免疫层析,免疫传感器,和其他人,还进行了报告和评估。最后,简要讨论了与商业试剂盒验证研究相关的数据.我们的结果表明,有几种抗原具有开发准确诊断工具的巨大潜力,但需要进一步的测试。批判性分析还带来了一些见解,这些见解对于CVL血清诊断的更可靠的工具的更自信的诊断开发是有用的。
Canine visceral leishmaniasis (CVL) is the most aggressive and lethal form of leishmaniasis manifesting in dogs and represents a major public health concern. Although there are sufficiently sensitive molecular tools for CVL diagnosis, they are not accessible at the main points of disease dissemination, in which context
serodiagnosis has been used as an alternative tool on the epidemiological control. As an attempt to develop more accurate immunodiagnostic assays, many antigens have been tested over the years, on different platforms. This
review aimed to access studies reporting new antigens that can be applied for CVL
serodiagnosis. Articles published from January of 2016 to March of 2021 were retrieved from Google Scholar, Science Direct, and PubMed, using \"Canine Visceral Leishmaniasis\" and \"
Serodiagnosis\" as keywords. In total, 1527 articles were identified, of which 42 were selected based on exclusion factors. Sensitivity, specificity, sample size, and sample quality data were extracted by manual curation and analyzed. Of the selected articles, 26 contemplated ELISA, which enabled a more thorough comparison and a critical
review of these studies. Soluble Leishmania Antigens (SLA) and the A2 protein were used as controls in 53.8 and 46.15 % of these articles, respectively, and were evaluated separately; their frequent use was questioned. Subsequently, articles that evaluated other assay platforms, such as immunochromatography, immunosensors, and others, were also reported and evaluated. Finally, data relative to validation studies of commercial kits were briefly discussed. Our results show that there are several antigens with great potential for the development of accurate diagnostic tools, but further testing is required. The critical analysis also brings insights that can be useful for more assertive diagnostic development of more robust tools for CVL
serodiagnosis.